Vaxcyte’s SEC filings as charts: revenue and profit, valuation, how it makes money, cash and debt.
Read from proxy statements, a fiscal year at a time.
Read from proxy statements, a fiscal year at a time.
From the pay-versus-performance table of each proxy statement. “Actually paid” values the stock awards at the year’s closing price, so it falls when the stock does. The returns are the newest proxy’s, from the start of its first year, against the peer group it names.
Source: PCVX’s SEC filings (10-K and 10-Q), the same figures as its financial statements. Fiscal years are as reported; a fourth quarter is the year less its first three where the company files none of its own; TTM is the trailing twelve months. A balance or a valuation beside the fiscal years is the newest quarter’s. Valuation is at each period’s end, at that day’s close. Debt is short- and long-term borrowings as filed, leases apart; cash includes short-term investments. Interest cover is operating income over interest expense. Revenue by segment, product and region is each 10-K’s own table, named as the filing names its rows, and only where the rows add up to the revenue the filing reports. The backlog is the remaining performance obligation the filings state: revenue under contract and not yet earned. Debt due by year is the newest 10-K’s schedule of long-term debt principal. Not investment advice.
